CN101809020A - 作为CDK抑制剂的perharidines - Google Patents

作为CDK抑制剂的perharidines Download PDF

Info

Publication number
CN101809020A
CN101809020A CN200880106879A CN200880106879A CN101809020A CN 101809020 A CN101809020 A CN 101809020A CN 200880106879 A CN200880106879 A CN 200880106879A CN 200880106879 A CN200880106879 A CN 200880106879A CN 101809020 A CN101809020 A CN 101809020A
Authority
CN
China
Prior art keywords
group
formula
groups
compound
halogen atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880106879A
Other languages
English (en)
Chinese (zh)
Inventor
L·梅耶
K·贝塔耶布
H·嘉伦斯
L·德曼格
N·欧玛塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Rennes 1
Universite Paris Descartes
Original Assignee
Universite de Rennes 1
Universite Paris Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Rennes 1, Universite Paris Descartes filed Critical Universite de Rennes 1
Publication of CN101809020A publication Critical patent/CN101809020A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN200880106879A 2007-09-12 2008-09-12 作为CDK抑制剂的perharidines Pending CN101809020A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB2007/003655 WO2009034411A1 (en) 2007-09-12 2007-09-12 Perharidines as cdk inhibitors
WOPCT/IB2007/003655 2007-09-12
PCT/IB2008/003106 WO2009034475A2 (en) 2007-09-12 2008-09-12 Perharidines as cdk inhibitors

Publications (1)

Publication Number Publication Date
CN101809020A true CN101809020A (zh) 2010-08-18

Family

ID=39773126

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880106879A Pending CN101809020A (zh) 2007-09-12 2008-09-12 作为CDK抑制剂的perharidines

Country Status (10)

Country Link
US (1) US8450342B2 (enExample)
EP (1) EP2185557A2 (enExample)
JP (1) JP2010539155A (enExample)
KR (1) KR20100075907A (enExample)
CN (1) CN101809020A (enExample)
BR (1) BRPI0816799A2 (enExample)
CA (1) CA2699040A1 (enExample)
MX (1) MX2010002477A (enExample)
RU (1) RU2498984C2 (enExample)
WO (2) WO2009034411A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105481858A (zh) * 2014-10-11 2016-04-13 上海医药集团股份有限公司 一种含氮稠杂环化合物、其制备方法、组合物及应用
CN111217814A (zh) * 2018-11-26 2020-06-02 天津科技大学 一类联哌啶衍生物及其作为抗肿瘤药物的应用
CN115104576A (zh) * 2022-07-12 2022-09-27 河北医科大学 Cdk5调控eEF2在糖尿病肾病防治中的操作方法
CN118598874A (zh) * 2024-05-21 2024-09-06 江南大学 一种取代的9h嘌呤类化合物、药物组合物及其用途

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013059634A1 (en) 2011-10-20 2013-04-25 The Regents Of The University Of California Use of cdk9 inhibitors to reduce cartilage degradation
HRP20250059T1 (hr) 2018-09-10 2025-03-28 Mirati Therapeutics, Inc. Kombinirane terapije
EP4079733A1 (en) 2019-12-20 2022-10-26 Evopoint Biosciences Co., Ltd. Heterocyclic compound, and pharmaceutical composition thereof, preparation method therefor, intermediate thereof and application thereof
GB202108572D0 (en) * 2021-06-16 2021-07-28 Carrick Therapeutics Ltd Therapeutic compounds and their use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU566842A1 (ru) * 1976-01-06 1977-07-30 Донецкое Отделение Физико-Органической Химии Института Физической Химии Им.Л.В.Писаржевского Ан Украинской Сср Способ получени замещенных имидазопиридинов
AU7738000A (en) * 1999-09-30 2001-04-30 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
UA74593C2 (en) * 2000-12-08 2006-01-16 3M Innovative Properties Co Substituted imidazopyridines
EP1352910A1 (en) * 2002-04-10 2003-10-15 Grünenthal GmbH New analogs of nitrobenzylthioinosine
JP4903997B2 (ja) * 2002-07-02 2012-03-28 サザン リサーチ インスティチュート ＦｔｓＺの阻害剤およびそれらの用途
US20080125404A1 (en) * 2004-08-27 2008-05-29 Cyclacel Limited Purine and Pyrimidine Cdk Inhitbitors and Their use for The Treatment of Autoimmune Diseases
TW200616624A (en) * 2004-09-09 2006-06-01 Solvay Pharm Bv 2-substituted-1-deaza purine derivatives with adenosine receptor modulating activity
WO2006061380A2 (en) * 2004-12-09 2006-06-15 Altana Pharma Ag SUBSTITUTED IMIDAZO[4,5-b]PYRIDINES AS INHIBITORS OF GASTRIC ACID SECRETION

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105481858A (zh) * 2014-10-11 2016-04-13 上海医药集团股份有限公司 一种含氮稠杂环化合物、其制备方法、组合物及应用
CN105481858B (zh) * 2014-10-11 2019-05-17 上海医药集团股份有限公司 一种含氮稠杂环化合物、其制备方法、组合物及应用
CN111217814A (zh) * 2018-11-26 2020-06-02 天津科技大学 一类联哌啶衍生物及其作为抗肿瘤药物的应用
WO2020108407A1 (zh) * 2018-11-26 2020-06-04 天津科技大学 一类联哌啶衍生物作为抗肿瘤药物
CN111217814B (zh) * 2018-11-26 2022-08-26 天津科技大学 一类联哌啶衍生物及其作为抗肿瘤药物的应用
CN115104576A (zh) * 2022-07-12 2022-09-27 河北医科大学 Cdk5调控eEF2在糖尿病肾病防治中的操作方法
CN118598874A (zh) * 2024-05-21 2024-09-06 江南大学 一种取代的9h嘌呤类化合物、药物组合物及其用途

Also Published As

Publication number Publication date
EP2185557A2 (en) 2010-05-19
RU2498984C2 (ru) 2013-11-20
WO2009034475A3 (en) 2009-08-13
WO2009034411A1 (en) 2009-03-19
BRPI0816799A2 (pt) 2015-03-03
KR20100075907A (ko) 2010-07-05
JP2010539155A (ja) 2010-12-16
CA2699040A1 (en) 2009-03-19
US20100280065A1 (en) 2010-11-04
MX2010002477A (es) 2010-08-09
RU2010108507A (ru) 2011-10-20
US8450342B2 (en) 2013-05-28
WO2009034475A2 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
US11833153B2 (en) N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors
JP6276762B2 (ja) キナーゼ阻害剤として活性な置換ピロール類
JP5406725B2 (ja) タンパク質キナーゼ阻害剤として有用な化合物
CN101809020A (zh) 作为CDK抑制剂的perharidines
AU2014225155B2 (en) Pyridopyrimidine or pyrimidopyrimidine compound, preparation method, pharmaceutical composition and use thereof
JP5796094B2 (ja) イミダゾピラジン
KR20120096474A (ko) 단백질 키나제 억제제로서 유용한 피리미딘 유도체의 제조 방법
KR20080016659A (ko) 단백질 키나제의 억제제로서 유용한 피롤로피리딘
KR20110033239A (ko) 단백질 키나제 억제제
JP6283688B2 (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての新規なピラゾール置換のイミダゾピラジン
KR20120094920A (ko) 단백질 키나제 억제제로서 유용한 피리미딘 유도체의 제조 방법
JP2010509203A (ja) 置換されている８−ピペリジニル−２−ピリジニル−ピリミド［１，２−ａ］ピリミジン−６−オンおよび８−ピペリジニル−２−ピリミジニル−ピリミド［１，２−ａ］ピリミジン−６−オン誘導体
JP4484524B2 (ja) １−［アルキル］、１−［（ヘテロアリール）アルキル］および１−［（アリール）アルキル］−７−（ピリミジン−４−イル）−イミダゾ［１，２−ａ］ピリミジン−５（１Ｈ）−オン誘導体
CN115490671A (zh) Parp7抑制剂及其制备方法
EP4157844A1 (en) 4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridine-1-(2h)-carboxamide derivatives as limk and/or rock kinases inhibitors for use in the treatment of cancer
KR101556317B1 (ko) Ｒｏｓ 카이네이즈 저해활성을 갖는 2,4,6-삼치환된 피리미딘 화합물
JP7157084B2 (ja) キナーゼＪＡＫ阻害剤としてのピラゾロ［１，５－ａ］ピリミジン誘導体
CN120943837A (zh) 作为酪氨酸激酶抑制剂的杂环化合物
HK1217197B (en) Pyridopyrimidine or pyrimidopyrimidine compound, preparation method, pharmaceutical composition and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20100818